Immunai has signed an agreement with AstraZeneca to develop a therapeutic target for inflammatory bowel disease (IBD), marking a shift from their existing oncology-focused collaboration …
Read More
For many years the focus of therapeutic developments and scientific research was directed at the genome and proteins. Yet, there is a completely different level …
Read More
U.S. biotech company Nabla Bio has signed a second major research partnership with Japan’s Takeda Pharmaceutical Co. (4502.T), expanding their collaboration in artificial intelligence-driven drug …
Read More
Since the discovery of its mechanism in 2012, CRISPR-based gene editing has turned from basic discovery into a bioengineering tool now penetrating biomedicine and enabling …
Read More
Decentralized clinical trials (DCTs) are not a recent invention, but their adoption has accelerated as logistical complexity, geographic dispersion, and patient burden have come under …
Read More
Nowadays, mobile devices are ubiquitous with an estimated number of smartphones and tablet PCs to exceed two billion globally. The availability of internet connection in …
Read More
